Teladoc (NYSE:TDOC) issued an update on its FY18 earnings guidance on Tuesday morning. The company provided EPS guidance of -$1.36 to -$1.41 for the period, compared to the Thomson Reuters consensus EPS estimate of ($1.14). The company issued revenue guidance of $350 million to $360 million, compared to the consensus revenue estimate of $356.43 million.Teladoc also updated its Q1 guidance to -$0.43 to -$0.45 EPS.
Teladoc (NYSE:TDOC) traded up $0.15 during trading hours on Wednesday, hitting $42.95. The stock had a trading volume of 1,028,778 shares, compared to its average volume of 1,183,280. The company has a market cap of $2,610.00 and a price-to-earnings ratio of -20.77. Teladoc has a 1-year low of $21.25 and a 1-year high of $44.65. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.87 and a quick ratio of 3.87.
TDOC has been the subject of several analyst reports. Deutsche Bank initiated coverage on Teladoc in a research note on Friday, December 8th. They issued a buy rating and a $39.00 price objective for the company. KeyCorp reaffirmed a buy rating and issued a $39.00 price objective on shares of Teladoc in a research note on Monday, December 4th. Canaccord Genuity raised their price objective on Teladoc from $42.00 to $43.00 and gave the company a buy rating in a research note on Wednesday, January 31st. Jefferies Group started coverage on Teladoc in a research note on Friday, January 26th. They issued a buy rating and a $40.00 price objective for the company. Finally, Citigroup started coverage on Teladoc in a research note on Thursday, January 4th. They set a buy rating for the company. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $40.71.
In other Teladoc news, insider Adam C. Vandervoort sold 47,123 shares of the firm’s stock in a transaction on Monday, March 5th. The stock was sold at an average price of $39.36, for a total transaction of $1,854,761.28. Following the transaction, the insider now directly owns 19,338 shares in the company, valued at approximately $761,143.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Peter A. Mcclennen sold 27,533 shares of the firm’s stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $43.01, for a total value of $1,184,194.33. The disclosure for this sale can be found here. Insiders have sold a total of 324,494 shares of company stock valued at $12,935,147 over the last three months. 4.47% of the stock is owned by corporate insiders.
WARNING: This story was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://ledgergazette.com/2018/03/14/teladoc-tdoc-releases-fy18-earnings-guidance.html.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.